- Home
- AEF vs VNDA Comparison
AEF vs VNDA Comparison
Compare AEF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEF
- VNDA
- Stock Information
- Founded
- AEF 1989
- VNDA 2002
- Country
- AEF United States
- VNDA United States
- Employees
- AEF N/A
- VNDA N/A
- Industry
- AEF Finance/Investors Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- AEF Finance
- VNDA Health Care
- Exchange
- AEF Nasdaq
- VNDA Nasdaq
- Market Cap
- AEF 237.8M
- VNDA 237.9M
- IPO Year
- AEF N/A
- VNDA 2006
- Fundamental
- Price
- AEF $4.84
- VNDA $4.33
- Analyst Decision
- AEF
- VNDA Strong Buy
- Analyst Count
- AEF 0
- VNDA 2
- Target Price
- AEF N/A
- VNDA $16.50
- AVG Volume (30 Days)
- AEF 92.5K
- VNDA 754.6K
- Earning Date
- AEF 01-01-0001
- VNDA 05-07-2025
- Dividend Yield
- AEF 7.13%
- VNDA N/A
- EPS Growth
- AEF N/A
- VNDA N/A
- EPS
- AEF 0.57
- VNDA N/A
- Revenue
- AEF N/A
- VNDA $198,772,000.00
- Revenue This Year
- AEF N/A
- VNDA $14.36
- Revenue Next Year
- AEF N/A
- VNDA $44.53
- P/E Ratio
- AEF $8.86
- VNDA N/A
- Revenue Growth
- AEF N/A
- VNDA 3.18
- 52 Week Low
- AEF $4.40
- VNDA $3.85
- 52 Week High
- AEF $5.53
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- AEF 46.04
- VNDA 43.42
- Support Level
- AEF $4.80
- VNDA $4.27
- Resistance Level
- AEF $4.78
- VNDA $4.46
- Average True Range (ATR)
- AEF 0.15
- VNDA 0.22
- MACD
- AEF 0.02
- VNDA 0.01
- Stochastic Oscillator
- AEF 65.08
- VNDA 54.55
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. It invests in the public equity and fixed income markets of Chile. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, Private Equity, telecommunication services, healthcare, real estate and industrials.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.